HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade.

AbstractOBJECTIVE:
We investigated the contribution of reduced nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase-dependent reactive oxygen species (ROS) generation to the pathogenesis of diastolic heart failure (DHF) in Dahl salt-sensitive (DS) hypertensive rats, with the aim of testing our hypothesis that the cardioprotective effects of angiotensin II (Ang II) blockade are provided by the suppression of this pathway.
METHODS:
DS rats were maintained on high (H: 8.0% NaCl) or low (L: 0.3% NaCl) salt diets from age 7 to 17 weeks. DS/H rats were also treated with candesartan cilexetil (10 mg/kg per day, orally) or a superoxide dismutase mimetic, tempol (3 mmol/l in drinking water) from age 7 to 17 weeks.
RESULTS:
DS/H rats represented hypertension, left ventricular (LV) relaxation abnormality and myocardial stiffening with preserved systolic heart function. As compared with DS/L rats, DS/H rats showed higher levels of transforming growth factor-beta (TGF-beta), connective tissue growth factor (CTGF), p22phox and gp91phox mRNA expression, NADPH oxidase activity and thiobarbituric acid-reactive substance (TBARS) contents in LV tissues. Gene expression of uncoupling protein-2 (UCP-2), an inner mitochondrial membrane proton transporter, was also 2.8 +/- 0.5-fold higher. In DS/H rats, treatment with candesartan did not alter blood pressure, but resulted in a marked improvement of the hemodynamic deterioration; these therapeutic effects were accompanied by decreases in myocardial NADPH oxidase activity, TBARS contents and the expression of TGF-beta, CTGF, p22phox, gp91phox and UCP-2. Similar therapeutic effects were provided by treatment with tempol in DS/H rats.
CONCLUSIONS:
Our data suggest that NADPH oxidase-mediated ROS production contributes to the pathogenesis of DHF in DS hypertensive rats, and that the cardioprotective effects of AngII blockade are, at least partially, mediated through the suppression of this pathway.
AuthorsPeng Guo, Akira Nishiyama, Matlubur Rahman, Yukiko Nagai, Takahisa Noma, Tsunetatsu Namba, Makoto Ishizawa, Kazushi Murakami, Akira Miyatake, Shoji Kimura, Katsufumi Mizushige, Youichi Abe, Koji Ohmori, Masakazu Kohno
JournalJournal of hypertension (J Hypertens) Vol. 24 Issue 6 Pg. 1097-104 (Jun 2006) ISSN: 0263-6352 [Print] England
PMID16685210 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • CCN2 protein, rat
  • Immediate-Early Proteins
  • Intercellular Signaling Peptides and Proteins
  • Ion Channels
  • Membrane Transport Proteins
  • Mitochondrial Proteins
  • Reactive Oxygen Species
  • Thiobarbituric Acid Reactive Substances
  • Transforming Growth Factor beta
  • Ucp2 protein, rat
  • Uncoupling Protein 2
  • Angiotensin II
  • Natriuretic Peptide, Brain
  • Connective Tissue Growth Factor
  • Collagen
  • NADPH Oxidases
Topics
  • Angiotensin II (physiology)
  • Animals
  • Blood Pressure (physiology)
  • Collagen (metabolism)
  • Connective Tissue Growth Factor
  • Diastole (physiology)
  • Gene Expression
  • Heart Failure (metabolism, pathology, physiopathology)
  • Heart Ventricles (metabolism, pathology)
  • Hypertension (physiopathology)
  • Immediate-Early Proteins (metabolism)
  • Intercellular Signaling Peptides and Proteins (metabolism)
  • Ion Channels
  • Lung (pathology)
  • Male
  • Membrane Transport Proteins (metabolism)
  • Mitochondrial Proteins (metabolism)
  • Myocardium (metabolism)
  • NADPH Oxidases (metabolism)
  • Natriuretic Peptide, Brain (metabolism)
  • Organ Size (physiology)
  • Rats
  • Rats, Inbred Dahl
  • Reactive Oxygen Species (metabolism)
  • Thiobarbituric Acid Reactive Substances (metabolism)
  • Transforming Growth Factor beta (metabolism)
  • Uncoupling Protein 2
  • Ventricular Dysfunction, Left (metabolism, pathology, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: